MPM Oncology Impact Management »

Belite Bio shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Belite Bio (BLTE) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Belite Bio

Tip: Access up to 7 years of quarterly data

All positions including Belite Bio held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Belite Bio by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $14M 88k 159.96

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Madrigal Pharmaceuticals Common (MDGL)
Liquidia Corp Common (LQDA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Uniqure NV Common (QURE)
PTC Therapeutics Common (PTCT)
Syndax Pharmaceuticals Common (SNDX)
Dyne Therapeutics Common (DYN)
Tarsus Pharmaceuticals Common (TARS)
Stoke Therapeutics Common (STOK)
Alumis Common (ALMS)
Urogen Pharma Common (URGN)

View all positions for MPM Oncology Impact Management

Top funds holding Belite Bio

Darwin Global Management
RA Capital Management
Rtw Investments
Eventide Asset Management
Vestal Point Capital
Point72 Asset Management
Deerfield Management Company
Marshall Wace
UBS Group
MPM Oncology Impact Management
Holocene Advisors
Western Standard
Perceptive Advisors
Goldman Sachs Group
Soleus Capital Management

View all funds holding Belite Bio